

Whitepaper

# The Legal Implications of an Un-Digitized Lab

# Table of contents

Legal Considerations for the Life Science Lab .....	4
Real-World Life Science Legal Issues .....	5
Famous Cases and Poor Data from .....	8
the Life Science Industry	
Conclusion .....	9





**No one likes legal trouble. And the life science industry is no exception. With huge court cases over patent disputes and unintentional errors, scientists are not immune from the tendrils of legal action and the court system.**

The possibility of legal action increases when labs don't have protective mechanisms around their most coveted asset: Their data. Laboratory data is often considered sensitive and confidential, particularly in the case of medical, pharmaceutical, or biotechnology research, where intellectual property (IP) or human data is involved. If this data isn't properly stored, it can be more difficult to ensure its security and prevent unauthorized access, loss, or theft. This can lead to legal consequences such as breach of confidentiality, loss of IP, and potential liability for damages.

In addition, many regulatory agencies require that laboratory data be recorded and stored digitally in a specific format, such as electronic lab notebooks, to ensure the accuracy, traceability, and reproducibility of research results.

Failure to comply with these regulations can result in fines, penalties, or even revocation of licenses or permits.

Moreover, in the event of a legal dispute, audit, or investigation, the absence of digital records can hinder the ability to provide evidence or defend against allegations. This could potentially result in adverse legal judgments, fines, or reputational damage.

Digitalization of laboratories and their data has become necessary for many labs operating in regulated environments. In the following whitepaper, we'll dive into some legal problems that can arise when labs don't employ digital laboratory management systems and how they can help with regulatory compliance and staying out of legal hot water.

# Legal Considerations for the Life Science Lab

Life science laboratories are subject to various laws and regulations to ensure personnel safety and integrity of research and clinical work. These laws and regulations vary depending on the type of laboratory and its activities, but common regulatory bodies include the Food and Drug Administration (FDA), the Environmental Protection Agency (EPA), and the Occupational Safety and Health Administration (OSHA).

Whether a lab operates in academia, industry, or government, compliance with regulations related to research ethics, animal and human subject welfare, hazardous waste disposal, biohazard safety, and quality control and assurance may be necessary. Additionally, laboratories are often subject to inspection and audit by regulatory agencies and can face significant legal and financial consequences for non-compliance.

Here are a few potential legal implications to consider:

- **Regulatory Compliance**

Depending on the nature of your lab and the industry you operate in, you may be subject to regulations that require certain types of data to be recorded and stored in a specific format. For example, if you run a medical lab, you may be required to comply with HIPAA regulations that govern the privacy and security of patient health information.

- **Quality Control**

Products produced in the life sciences undergo rigorous quality control testing to ensure accurate and reliable results and protect human safety. Quality control issues can lead to unnecessary harm to individuals or property damage due to errors or inconsistencies.





### • Intellectual Property

If you are developing new technologies or processes, you may need to patent your inventions. Protecting these inventions through intellectual property requires rigorous tracking of data and documentation of when, where, and how innovation occurred. This has implications across all areas of life science, with several high-profile IP cases coming down to questions about when, down to the minute, a scientific discovery occurred. Management systems and how they can help with regulatory compliance and staying out of legal hot water.

### • Liability

If your lab produces products or services used by others, you may be liable for any harm resulting from their use. Tracking, testing, and collecting data is essential to identifying potential issues.

### • Litigation

In the event of legal disputes, such as product liability claims or breach of contract lawsuits, adequate documentation from the lab may need to be provided in court to prove your case. This may be challenging to do without proper record-keeping and accurate data management.

### • Data Privacy

Labs may handle sensitive information, such as patient, genetic, and personal identifying information. Managing this data requires proper security, encryption, and storage to prevent unauthorized access or data loss. Failure to protect sensitive data can result in legal liability, fines, and damage to the lab's reputation.

## Real-World Life Science Legal Issues

The theoretical complications above can and have had real-world consequences. Let's get a better sense of how these can play out with some concrete examples.

### The Cost of IP Disputes in the Biotechnology Industry

The costs of IP disputes in the biotech industry can be high, including legal fees, damages, loss of revenue, and reputational harm. IP disputes in biotech can arise from various issues, such as patents, trademarks, copyrights, and trade secrets. Some common types of disputes include patent infringement, licensing disagreements, and disputes over ownership or inventorship of a patent.

The cost of an IP dispute can vary depending on the nature and complexity of the case, the jurisdiction, and legal fees. A study by the American Intellectual Property Law Association found that the median cost of a patent dispute with less than \$1 million at risk was \$650,000, while the median cost of a patent dispute with \$25 million or more at risk was \$5.5 million.



# Real-World IP Disputes

There have been a significant number of patent disputes in biotech. Often, with the amount of money at stake, patient populations involved, and notoriety of the researcher involved, these court cases spill over from the life science world into the larger public sphere. Take a look at the examples below for a snapshot of some of the more prominent cases for biotech and pharma:

**CRISPR/Cas9:** The CRISPR/Cas9 gene editing technology has been the subject of several patent disputes between the Broad Institute of MIT and Harvard and the University of California, Berkeley. The dispute centered around who first invented the technology and who should be awarded the patent rights. In 2017, the U.S. Patent and Trademark Office (USPTO) ruled in favor of the Broad Institute, stating that their researchers were the first to invent the use of CRISPR/Cas9 in eukaryotic cells.

**Herceptin:** In 2002, the biotechnology company Chiron filed a lawsuit against Genentech, claiming that Genentech's breast cancer drug, Herceptin, infringed on discoveries made by Chiron. Chiron lost the case after a Federal District Court rejected their claims.

**Humira:** AbbVie's Humira is one of the best-selling drugs in the world, used to treat a variety of autoimmune diseases. In 2018, the company settled a patent dispute with Boehringer Ingelheim, which had developed a biosimilar version of Humira. As part of the settlement, Boehringer Ingelheim agreed to delay the launch of its biosimilar in the US until 2023.

These are just a few examples of the many IP disputes that have arisen in the biotechnology industry. With so much innovation and investment in this field, more conflicts will likely occur in the future.



- **Retractions of Published Scientific Literature**

Scientific paper retractions occur when the journal or authors withdraw a published scientific paper due to errors, misconduct, or other issues that undermine the validity of the research findings. Retractions are an important part of the scientific process, as they help to ensure the accuracy and reliability of the scientific literature.

Here are some of the reasons a paper might get retracted.

- **Scientific Misconduct**

Misconduct is one of the most common reasons why scientific papers are retracted. Misconduct can include data fabrication, falsification, plagiarism, and other forms of scientific misconduct. Papers that are found to contain fraudulent or manipulated data are likely to be retracted.

- **Unintentional Error**

Sometimes errors can occur during research, leading to incorrect or unreliable data. Errors can include mistakes in methodology, statistical analysis, and data interpretation. If errors are discovered after publication, the paper may need to be retracted.

- **Duplicate Publication**

Duplicate publication occurs when authors submit the same data or findings to multiple journals without acknowledging the prior publication. Duplicate publication is considered unethical and can result in retractions.

- **Unreliable Data**

Unreliable data can result from inadequate experimental design, faulty instrumentation, or other technical issues. If the data cannot be replicated or verified, the paper may be retracted.

- **Ethical Concerns**

Ethical concerns can arise when papers involve human or animal subjects or the use of biological agents that pose risks to public health. Papers that are found to violate ethical standards or regulations may be retracted.

- **Fabrication or Falsification of Data**

This is one of the most severe reasons for retraction. If the data presented in a paper is fabricated or falsified, it is considered research misconduct and can lead to the paper's retraction.

- **Plagiarism**

If a paper includes significant amounts of text or data that have been copied from other sources without proper attribution, it can be retracted for plagiarism.

- **Retractions of Published Scientific Literature**

If errors or inaccuracies are discovered in the data or analysis presented in a paper, the paper may need to be retracted. This can happen if the errors undermine the paper's conclusions or if they are significant enough to call into question the validity of the entire study.

- **Authorship Issues**

If there are disputes about authorship or conflicts of interest among the authors of a paper, it may be retracted. This can happen if some authors were not properly credited for their contributions or if there are undisclosed conflicts of interest that could affect the integrity of the study.

## What is RetractionWatch?

Retraction Watch is a blog that was launched in 2010 by Adam Marcus and Ivan Oransky, two science journalists who specialize in reporting on scientific retractions. The blog covers retractions of scientific papers due to various reasons such as fraud, errors, or ethical concerns. It provides a forum for discussing the issues surrounding scientific misconduct and the scientific publishing process.

Retraction Watch publishes news stories, analyses, and commentary on retractions from various fields, including biology, medicine, psychology, chemistry, physics, and more. The blog also maintains a database of retractions, searchable by author, journal, and other criteria.

Retraction Watch has gained a reputation as a leading source of information on scientific retractions and has been cited in many news articles and academic papers. The blog won several awards, including the Society of Professional Journalists Sigma Delta Chi Award for Online Reporting in 2014.

## Famous Cases and Poor Data from the Life Science Industry

Several high-profile disputes in the biotech industry have been attributed to poor data, leading to significant financial and reputational losses. Here are a few examples:

**Theranos:** This is perhaps the most well-known example of a biotech company that faced legal and financial troubles due to poor data. Theranos claimed to have developed a blood-testing technology that could revolutionize the industry, but investigations revealed that the technology was flawed and the company's data was unreliable. The scandal led to a criminal investigations, lawsuits, and the eventual collapse of the company. Theranos' founder, Elizabeth Holmes, was recently sentenced to 11 years in prison for defrauding investors.

**Celgene:** In 2017, the biotech company Celgene settled a lawsuit for \$280 million, alleging that the company had made false claims about the efficacy of its cancer drugs. The lawsuit alleged that Celgene had provided incomplete or misleading

data to the FDA, which led to the approval of drugs that were not as effective as advertised.

**Amgen:** In 2016, Amgen settled a lawsuit for \$71 million related to the marketing of its drug Aranesp. The lawsuit alleged that Amgen had promoted the drug for off-label uses without adequate data to support the claims.

**Genentech:** In 2011, Genentech settled a lawsuit for \$20 million related to allegations that the company had misrepresented the results of a clinical trial for its drug Rituxan. The lawsuit alleged that the company had altered data to make the drug appear more effective than it was.

These examples demonstrate the importance of accurate and reliable data in the biotech industry. Poor data can lead to legal and financial troubles, damage to a company's reputation, and harm to patients who rely on the products being developed.





# Conclusion

An un-digitized lab can have several legal implications, including difficulty complying with regulations, quality control issues, intellectual property challenges, and increased liability. It's essential to consider these factors when deciding whether to digitize your lab and to work with legal professionals to ensure that you comply with relevant laws and regulations.

Like everything, digitalization and legal compliance is a process: An Olympic athlete doesn't show up the day of the competition with no prep. It takes grit and hard work to perform R&D or commercialize a product. These day-to-day data collection in a compliant and secure environment, enables cutting-edge diagnostics and therapeutics to enter the market, and improve our quality of life.

If you're interested in starting your digital journey now, [contact us](#) today!

*Author: Zareh Zurabyan*



---

✉ [enquiries@elabnext.com](mailto:enquiries@elabnext.com)

☎ +31 50 720 00 55

All of our product specialists have a scientific background and are happy to discuss your needs. Schedule a demo for a free, no-obligation product demonstration.

CONTACT US